Labcorp Holdings Inc. (LH)
Labcorp Holdings Inc. (LH) is a leading global life sciences company providing diagnostic, testing, and clinical trial services. Founded in 1978, it offers a broad range of laboratory testing, drug development, and one-health solutions to healthcare providers, pharmaceutical companies, and biopharmaceutical firms. Headquartered in Burlington, North Carolina, Labcorp plays a key role in advancing personalized medicine and improving patient outcomes through its extensive diagnostic and research capabilities.
Dividend History
Investors can expect a dividend payout of $0.72 per share, scheduled to be distributed in 50 days on December 11, 2025
| Pay Date | Amount | Ex-Date | Record Date |
|---|---|---|---|
| December 11, 2025 | $0.72 | 2025-11-26 | 2025-11-26 |
| September 11, 2025 | $0.72 | 2025-08-28 | 2025-08-28 |
| June 11, 2025 | $0.72 | 2025-05-29 | 2025-05-29 |
| March 12, 2025 | $0.72 | 2025-02-27 | 2025-02-27 |
| December 13, 2024 | $0.72 | 2024-11-26 | 2024-11-26 |
Dividends Summary
- Labcorp Holdings Inc. has issued 15 dividend payments over the past 3 years
- The most recent dividend was paid 41 days ago, on September 11, 2025
- The highest dividend payed out to investors during this period was $0.72 per share
- The average dividend paid during this period was $0.72 per share.
Company News
Global fertility test market projected to grow from $7.92 billion in 2025 to $14.74 billion in 2033, driven by lifestyle changes, delayed pregnancies, and increasing infertility rates worldwide.
Labcorp Holdings Inc. announced a quarterly cash dividend of $0.72 per share, payable on December 11, 2025, to stockholders of record as of November 26, 2025.
Laboratory Corporation of America reported strong Q2 2025 financial results, with GAAP revenue of $3.53 billion, up 9.5% year-over-year. The company saw growth in both Diagnostics Laboratories and Biopharma Laboratory Services segments, raised full-year guidance, and continued to invest in innovative diagnostic technologies.
Labcorp reported strong Q2 2024 results, with adjusted EPS up 15.2% and revenues up 6.2% year-over-year. The company saw organic growth in its Diagnostics Laboratories segment, but cut its full-year adjusted EPS guidance due to the dilution impact of the Invitae acquisition.
